Nymox Announces $ 5 Million Registration Direct Offer, Canadian Business Journal

Irvine, California, March 18, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today to buy and sell 3,030,304 shares of common stock with institutional and accredited investors at a purchase price of $ 1.65. Announced that it has signed a final contract with. Per share of registered direct offering for total revenue of approximately $ 5 million before deducting placement agent fees and expenses. We also agreed to issue unregistered warrants to investors for the purchase of up to 3,030,304 shares of common stock in a simultaneous private placement. Warrants can be exercised immediately at an exercise price of $ 2.00 per share and will expire five years from the date of the valid registration notification for the underlying shares of the warrant. The end of the offering will take place on or around March 22, 2022, provided that the normal termination conditions are met.

Nymox plans to use the revenue for general corporate purposes, including working capital.

AGP / Alliance Global Partners is acting as the only deployment agent for this offering.

This common stock offer (excluding warrants or the common stock underlying the warrant) is carried out in accordance with a valid shelf registration statement on Form F-3 (File No. 333-261571) previously submitted to the US Securities and Exchange Commission. I will. Committee (“SEC”). A supplement to the prospectus explaining the terms of the proposed offering has been submitted to the SEC and is available on the SEC’s website at An electronic copy of the prospectus supplement is available from AGP / Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by phone (212) 624-2060, or email (prospectus @). You can get it at. Stakeholders should fully read the prospectus supplements and accompanying prospectuses, as well as any other documents submitted to the SEC by Nymox that are incorporated as references in the prospectus supplements and accompanying prospectuses.

The above warrants are offered in a private placement under Sections 4 (a) and (2) of the Securities Act of 1933 (the “Act”), under which Regulation D is promulgated and issued with the common stock underlying the warrants. I did. Not registered under the law or applicable state securities law. Therefore, warrants and underlying common stock may not be offered or sold in the United States unless subject to a valid registration statement or registration requirements of the law and applicable exemptions from such applicable state securities law. you can not.

This press release does not constitute an offer to sell or solicit a purchase, and in any state or jurisdiction where such offer, solicitation or sale is illegal prior to registration or qualification-based registration or qualification. , There is no sale of these securities. Securities law of such states or jurisdictions.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation specializes in therapeutic and diagnostic research and development, with a particular focus on products aimed at the unmet needs of the rapidly aging male population in developed countries. Our primary drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), was submitted to the FDA on March 3, 2022 in a New Drug Application (NDA). Europe.

For more information, please contact or 800-936-9669.

Description of future prospects

Unless the statement contained in this press release is an explanation of historical facts about Nymox, it is about future prospects that reflect management’s current beliefs and expectations made in accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. It’s a statement. Statement on the use of offering revenue, the end of the offering, the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer, and the estimated timing of further development of Fexapotide. includes.

Such forward-looking statements are material in which our clinical development program, future results, achievements, or outcomes may differ materially from those expressed or implied by the forward-looking statements. There are risks and uncertainties.

Such risks and uncertainties include, among other things, the regulatory approval process, the timing of Nymox’s regulatory submissions, Nymox’s substantive reliance on Fexapotide, Nymox’s commercialization plans and efforts, and Fexapotide’s. Availability or commercial potential. Nymox undertakes no obligation to update or revise any forward-looking statement. Details of the risks and uncertainties that actual results may differ from those presented in these forward-looking statements, as well as risks related to Nymox’s business in general, have been submitted to the US Securities and Exchange Commission. See our current and future reports on Nymox. And the exchange committee. The information contained in this press release is current as of the date of the press release and Nymox undertakes no obligation to update such information.

Contact us for more information:

Randall Lanham
Nymox Pharmaceutical Corporation

CBJ News Maker

Nymox Announces $ 5 Million Registration Direct Offer, Canadian Business Journal

Source link Nymox Announces $ 5 Million Registration Direct Offer, Canadian Business Journal

Related Articles

Back to top button